KCHC Annual Report and Accounts 2024-25 Spreads - Flipbook - Page 52
Notes to the financial statements
2023/24 comparatives
As
restated at
31 March
Transfers
2024
As restated
at 1 April
2023
Income
Expenditure
Gains/
(Losses)
£’000
£’000
£’000
£’000
£’000
£’000
100
-
-
-
(100)
-
Paediatric Liver Laboratories
345
98
(308)
-
-
135
David Hughes Special Trust
2,309
-
(300)
-
-
2,009
Transforming Liver Care (TLC) Appeal
189
454
(345)
-
(130)
168
Renal Legacy – Spratt
571
-
-
-
-
571
Parkinson's Research
-
116
(115)
-
-
1
Paediatric Liver Research (Flynn)
-
-
-
-
133
133
416
107
(265)
-
-
258
3,830
775
(1,333)
-
3
3,275
Clinical Funds
8,971
1,020
(957)
-
(137)
8,897
Fund for Strategic purpose
3,500
-
(130)
-
1,500
4,870
Development of capital projects
1,000
-
(27)
-
-
973
Office Fixtures & Fittings
33
-
-
-
1
34
Total designated funds
13,504
1,020
(1,114)
-
1,364
14,774
General funds
5,557
2,863
(3,612)
1,527
(1,267)
5,068
Total unrestricted funds
19,061
3,883
(4,726)
1,527
97
19,842
Total funds (as restated)
22,991
4,658
(6,059)
1,527
-
23,117
Endowment funds
Restricted funds
Other funds less than £100k
Total restricted funds
Unrestricted funds
Designated
Transfers include an internal allocation to each
designated and restricted fund equivalent to interest
52
S U P P O R T K I N G S .O R G .U K
earned based on the average value of the fund during
the year.
